Wolf Haldenstein Announces Investigation of Sarepta Therapeutics, Inc.,

  Wolf Haldenstein Announces Investigation of Sarepta Therapeutics, Inc.,

Business Wire

NEW YORK -- January 30, 2014

Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action
lawsuit has been filed in the United States District Court for the District of
Massachusetts on behalf of all persons or entities that purchased the
securities of Sarepta Therapeutics, Inc., (NASDAQ:SRPT) between July 24, 2013
and November 12, 2013.

The complaint alleges that during the Class Period, certain of the Company’s
officers and directors violated federal securities laws by making false and
misleading statements concerning the Company’s lead therapeutic candidate for
the treatment of Duchenne muscular dystrophy, eteplirsen.

Specifically, the Complaint alleges that multiple misleading statements were
made concerning: (1) the prospects of the Food and Drug Administration's
("FDA") acceptance for consideration of a New Drug Application ("NDA") for
eteplirsen based on Sarepta's Phase IIb study data set, and (2) the
significance of the Phase IIb data set.

On November 12, 2013, Sarepta disclosed that the FDA informed the Company that
its announced NDA filing for eteplirsen was premature. On this news, Sarepta's
stock price collapsed from its closing price of $36.56 per share on November
11, 2013 to $13.16 per share on November 12, 2013.

If you purchased Sarepta common stock during the Class Period, you may, no
later than March 28, 2014, request that the Court appoint you as lead
plaintiff of the class.

If you are a shareholder of Sarepta Therapeutics, Inc., (NASDAQ:SRPT) with a
loss of $75,000 or more and would like additional information concerning your
rights in this matter, please contact us at:

Gregory M. Nespole or Patrick Donovan
Wolf Haldenstein Adler Freeman & Herz LLP
270 Madison Avenue
New York, New York 10016

Phone Numbers:
(800) 575-0735
(212) 545-4600

Please visit the Wolf Haldenstein website (http://www.whafh.com) for more
information about the firm.

Wolf Haldenstein did not file the original complaint against Sarepta
Therapeutics, Inc.

Email:

Classmember@whafh.com, Nespole@whafh.com, Donovan@whafh.com or stone@whafh.com
and please reference “Sarepta Therapeutics, Inc., Investigation.”

Attorney Advertising. Prior results do not guarantee or predict a similar
outcome.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
800-575-0735 or 212-545-4600
Gregory M. Nespole
Nespole@whafh.com,
or
Patrick Donovan
Donovan@whafh.com
 
Press spacebar to pause and continue. Press esc to stop.